These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Biosimilar medicines. Scientific and legal disputes]. Dorantes Calderón B; Montes Escalante IM Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856 [TBL] [Abstract][Full Text] [Related]
4. [The story of biosimilars--chance or threat?]. Woroń J; Kocić I Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996 [TBL] [Abstract][Full Text] [Related]
5. Global regulatory standards for the approval of biosimilars. Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248 [TBL] [Abstract][Full Text] [Related]
6. The regulatory framework of biosimilars in the European Union. Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438 [TBL] [Abstract][Full Text] [Related]
7. A consistency approach for evaluation of biosimilar products. Tsou HH; Chang WJ; Hwang WS; Lai YH J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515 [TBL] [Abstract][Full Text] [Related]
8. Clinical trial development for biosimilars. Alten R; Cronstein BN Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550 [TBL] [Abstract][Full Text] [Related]
9. Biosimilar regulation in the EU. Kurki P; Ekman N Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076 [TBL] [Abstract][Full Text] [Related]
10. Biosimilars: A consideration of the regulations in the United States and European union. Daller J Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars and regulatory authorities. Minghetti P; Rocco P; Del Vecchio L; Locatelli F Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318 [TBL] [Abstract][Full Text] [Related]
12. Biosimilar safety considerations in clinical practice. Choy E; Jacobs IA Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025 [TBL] [Abstract][Full Text] [Related]
13. Biosimilar medicines--new challenges for a new class of medicine. Fox A J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245 [TBL] [Abstract][Full Text] [Related]
14. [Biosimilars versus original biologics. Similarities and differences from development to approval]. Windisch J Z Rheumatol; 2015 Oct; 74(8):672-81. PubMed ID: 26323591 [TBL] [Abstract][Full Text] [Related]
15. Effective pharmaceutical regulation needs alignment with doctors. Ebbers HC; Pieters T; Leufkens HG; Schellekens H Drug Discov Today; 2012 Feb; 17(3-4):100-3. PubMed ID: 22001600 [TBL] [Abstract][Full Text] [Related]
16. [Regulatory aspects of biosimilars. Myths and facts]. Schneider CK; Weise M Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104 [TBL] [Abstract][Full Text] [Related]
17. [Biosimilars: assessment of efficacy, safety and cost]. Domínguez-Gil Hurlé A Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855 [TBL] [Abstract][Full Text] [Related]